Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: A Children's Oncology Group report

Pediatric Blood and Cancer

Volumn 50, Issue 3, 2008, Pages 533-536

  Franklin, Janet L ^a   Seibel, Nita L ^b   Krailo, Mark ^c   Fu, Cecilia ^a   Adamson, Peter C ^e   Reaman, Gregory ^d  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Docetaxel; Leukemia; Phase 2 study

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGRANULOCYTOSIS; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER CHEMOTHERAPY; CANCER RELAPSE; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FEBRILE NEUTROPENIA; FEMALE; HEMATEMESIS; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPOKALEMIA; HYPOTENSION; LEUKOPENIA; LIVER TOXICITY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WOUND INFECTION;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE MARROW DISEASES; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEVER; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LEUKEMIA; LEUKEMIA, MYELOID; MALE; NEUTROPENIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SALVAGE THERAPY; TAXOIDS; TREATMENT FAILURE;

EID: 38549106510     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21313     Document Type: Article

References (25)

1. Cortes JE. Pazdur: Docetaxel. J Clin Oncol 1995;12:2643-2655.
2. Bissery MC, Guenard D, Gueritte-Voegelein F, et al. Experimental antitumor activity of Taxotere (RP 56976,NSC 628503), a Taxol analogue. Cancer Res 1991;51 4845-4852.
3. Pronk LC, Stoter G, Verweij J. Docetaxel (Taxotere): Single agent activity, development of combination treatment and reducing side effects. Cancer Treat Rev 1995;21:463-478.
4. Ringel I, Horwitz SBStudies, With RP. 56976 (Taxotere): A semisynthetic analogue of Taxol. J Natl Cancer Inst 1991;83:288-291.
5. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). New Eng J Med 1995;332:1004-1014.
6. RP 56976: Investigator's Brochure, V 5.0, Rhone-Poulene Rorer, 1997.
7. Riou JF, Naudin A. Effects of Taxotere on murine and human tumor cell lines. Biochem and Biophsy Res Comm 1992;187:164-170.
8. Nandy P, Fu C, Danenberg P, et al. Apoptosis induced by antimetabolites, taxanes, or asparaginase in vitro depends on the p53 status of leukemic cells. Abstr #4094. Proc Am Assoc Cancer Res 1998;89:602.
9. Kwock R, Nandy P, Solorzano M, et al. Combination regimens of fludarabine and ara-C followed by taxanes (docetaxel and paclitaxel) against human leukemic T-cell lines, CEM/O and CEM/ara-C/7A. Abstr # 2573. Proc Am Assoc Cancer Res 1996;37:377.
10. Consolini R, Pui CH, Behm FG, et al. In vitro cytotoxicity of docetaxel in childhood acute leukemias. J Clin Oncol 1998;16:907-913.
11. Majlessipour F, Avramis IA, Kwock R, et al. The combination regimen of Idarubicin and Taxotere is effective against human drug-resistant leukemic cell lines. Anticancer Res 2002;22:1361-1368.
12. Avramis VI, Nandy P, Kwock R, et al. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of Fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. Anticancer Res 1998;18:2327-2338.
13. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of Taxotere: Five-day schedule. J Natl Cancer Inst 1992;84:1781-1788.
14. Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as short intravenous infusion. Cancer Res 1993;53:1037-1042.
15. Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of Taxotere (RP56976) administered as a 24-hour infusion. Cancer Res 1993;53:523-527.
16. Tomiak R, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994;12:1458-1467.
17. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of Taxotere administered as either 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993;11:950-958.
18. Maurer AM, Masters GA, Haraf DJ, et al. Phase I study of Docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 1998;16:159-164.
19. Hainsworth JD, Burris FA III, Erland JB, et al. Phase I Trial of Docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-2168.
20. Blaney SM, Seibel NL, O'Brien M, et al. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: A collaborative Pediatric Branch, National Cancer Institute and Children's Cancer Group trial. J. Clin Oncol 1997;15:1538-1543.
21. Seibel NL, Blaney SM, O'Brien M, et al. Pediatric phase I trial of Docetaxel (D) with G-CSF: A collaborative Pediatric Branch, NCI and Children's Cancer Group trial. Clin Cancer Res 1999;5:733-737.
22. Zwerdling T, Krailo M, Monteleone P, et al. Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: A report from the Children's Oncology Group. Cancer 2006;106:1821-1828.
23. Lavelle F, Bissey MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Sem Oncol 1995;22:3-16.
24. Avramis IA, Kwock R, Avramis VI. Taxotere and Vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Anticancer Research 2001;21:2281-2286.
25. Dias S, Choy M, Alitalo K, et al. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002;99(6):2179-2184.